Objectives {7}
sleepiness, CMD
INFLAMMATION
The goal of this proposed study is to conduct a randomized controlled trial to test the efficacy of our behavioral sleep extension intervention on 24-h ambulatory BP (ABP) and other key biological and behavioral CMD risk factors among participants with short sleep duration and elevated BP/hypertension. The intervention will be completed over a 12-month period in 3 phases, intervention (weeks 0–8), maintenance (months 2–6), and follow-up (months 6–12), allowing us to test the short-term and extended effects of our intervention.Aim 1: To estimate the magnitude of the acute (8 weeks) and extended (12 months) effects of our behavioral sleep extension intervention compared to a health education control group on sleep durationAim 2: To test the effects of our behavioral sleep extension intervention compared with a health education control group on CMD risk factors including 24-h ABP, BMI, body fat, and CMD risk biomarkers (inflammation, glycemic control, lipids)Aim 3: To evaluate the effects of the intervention on key lifestyle behaviors (e.g., diet and physical activity) and patient-reported outcomes (sleep quality, sleepiness quality of life)